Clinical Trial Update: TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy [Phase 3]

View source ↗

Summary

A Phase 3 trial (TRITON-PN) evaluating Nucresiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy

Drugs mentioned

• Nucresiran (Nucresiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN | Phase 3 | Status: RECRUITING